Michael Chen ^UDM

Michael Chen is the Co-founder and CEO of neoX Biotech, a cutting-edge biotech company based in Beijing, China, with research teams in Shanghai, China, and Boston, USA. Under Chen's leadership, neoX integrates artificial intelligence, advanced biophysics, and high-throughput experimentation to pioneer highly differentiated therapeutics for unmet medical needs. The company focuses on discovering macromolecular and multi-specific drug modalities by gaining deep insights into dynamic protein-protein interactions (PPIs). neoX's AI/computation capabilities enable the development of a comprehensive pipeline that includes neoBiologics (antibody/nanobody, cytokine, and protein drugs) and neoDegrader (targeted protein degradation drugs). With multiple antibody-based drugs and PROTAC degraders in the pipeline, neoX actively seeks out-licensing opportunities and strategic Partnersships to advance its innovative assets globally.